<DOC>
	<DOCNO>NCT00000687</DOCNO>
	<brief_summary>To determine safety effectiveness combine zidovudine ( AZT ) interferon alfa-2a ( IFN-A2a ) treatment Kaposi 's sarcoma ( KS ) patient AIDS . It hop present study define rate treatment affect tumor also assess toxic effect combination treatment period time . In recent study , combination IFN-A2a AZT treatment patient AIDS-associated KS evaluate safe dos AZT IFN-A2a determine . In addition , appear substantial reduction KS lesion therapy . Potential benefit combine therapy include resolution KS lesion , prolong survival , decrease frequency severity opportunistic infection , improvement CD4 cell , decrease serum p24 antigen .</brief_summary>
	<brief_title>Phase II Study Zidovudine Recombinant Alpha-2A Interferon Treatment Patients With AIDS-Associated Kaposi 's Sarcoma</brief_title>
	<detailed_description>In recent study , combination IFN-A2a AZT treatment patient AIDS-associated KS evaluate safe dos AZT IFN-A2a determine . In addition , appear substantial reduction KS lesion therapy . Potential benefit combine therapy include resolution KS lesion , prolong survival , decrease frequency severity opportunistic infection , improvement CD4 cell , decrease serum p24 antigen . Following evaluation study , patient participate study receive IFN-A2a AZT . IFN-A2a administer single subcutaneous injection day . AZT give single capsule every 4 hour day total six capsule . The first phase treatment continue 8 week follow 1-week rest period , time AZT give . Subjects interruption interferon first 8 week study toxicity may skip rest period . Patients experience complete response place maintenance therapy . Patients without progression KS continue treatment AZT IFN-A2a complete response obtain study terminate , whichever come first . Patients complete anti-tumor response continue maintenance phase , receive IFN-A2a single injection 3 time week nonconsecutive day single capsule AZT q4h 6 x /day study terminate February 1 , 1992 . Patients required visit clinic weekly first 12 week ( except week 9 rest period ) , every week next 8 week , every month 52 week study every 3 month thereafter . Throughout study , frequent blood sample take monitor effectiveness safety treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Inhalation pentamidine prevention Pneumocystis carinii pneumonia ( PCP ) dose 300 mg every 4 week . AMENDED : Trimethoprim sulfamethoxazole dapsone maintenance phase study . Concurrent Treatment : Allowed : Blood transfusion . Patients must positive antibody HIV federally license ELISA test . All lab test must within 7 day entry study . Exclusion Criteria Concurrent Medication : Excluded : Other antiretroviral agent . Immunomodulators . Corticosteroids . Cytotoxic chemotherapy . Aspirin . H2 blocker . Barbiturates myelosuppressive drug particularly avoid may interfere metabolism enhance toxicity either zidovudine interferon alfa2a . Other experimental medication . Concurrent Treatment : Excluded : Radiation therapy . Patients prior experience Grade 4 toxicity zidovudine therapy exclude study . Prior Medication : Excluded : Interferon therapy . Excluded within 30 day study entry : Immunomodulators . Corticosteroids . Cytotoxic chemotherapeutic agent . Excluded within 14 day study entry : Zidovudine ( AZT ) . Prior Treatment : Excluded within 30 day study entry : Blood transfusion . Radiation therapy . Patients may follow disease symptom : Active opportunistic infection associate AIDS . Significant neurologic disease associate AIDS , manifest motor abnormality include impaired rapid eye movement ataxia , motor weakness low extremity , sensory deficit consistent peripheral neuropathy , bladder bowel incontinence . Internal organ involvement Kaposi 's sarcoma , i.e. , nonnodal visceral Kaposi 's sarcoma , exclude minimal gastrointestinal disease le 5 lesion . Tumorassociated edema . Current neoplasm Kaposi 's sarcoma . Significant cardiac disease , include recent history myocardial infarction significant current cardiac arrhythmia . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>